

Efficacy of rituximab treatment in a post-COVID-19 vaccine myositis overlapping to systemic sclerosis: a histological follow-up

Sirs,

We report this first case of myositis overlapping to systemic sclerosis (SSc) after the second dose of Corminaty INN-mRNA nucleoside COVID-19 vaccine (CV), responsive to rituximab (RT) treatment.

Even if vaccination has played a crucial role in reducing the severity in COVID-19 pandemic spread (1), adverse events have raised questions in susceptible individuals (2). Recent studies have suggested an association between CV and the onset of various inflammatory myopathies, in addition to autoimmune diseases (3-7).

Less than 4 weeks later the second dose of CV (July 2021), a 22-year-old female developed symmetric hands and wrists swelling, fixed cyanosis, puffy fingers with low positive skin score and pitting scars. These symptoms progressively worsened, complaining generalised body aches and muscle soreness. She had no history of previous COVID-19 (negative polymerase chain reaction) and other infections were excluded. Initially, anti-Spike Sars, quantitative IgG S1-RBD (288 BAU WHO/mL, normal value (nv) <28) and autoantibodies ANA IFI on cells HEp-2 (1:1280 speckled), antiU1RNP (>240 U/mL, <7 normal value), antiRNP70 (74 U/mL, <7 nv) and anti-nucleosomes (>200 U/mL, <20 nv) were increased. Power Doppler ultrasound (US) revealed activity (synovitis) in right hand and (tenosynovitis) in the shoulders. Baseline capillaroscopy revealed multiple crossings and tortuous capillaries.

After the diagnosis of undifferentiated connective tissue disease in January 2022, she was initially treated with low dosage of hydroxychloroquine, prednisone and pentoxifylline. However, in April 2022, her symptoms worsened with increased joint pain and initial ulcer of the third finger of the right hand. The treatment was adjusted with prostaglandins *i.v.* monthly infusions and amlodipine, discontinuing hydroxychloroquine (October 2022) for idiosyncratic skin reaction at increasing dose.

After an initial improvement of ulcer and puffy fingers in January 2023, Raynaud relapsed at hands and lips, as well as stiffness of the skin (hands and face) and upper and lower limbs pain with an increase of aldolase 56 U/mL (nv 0-7.6) and CK 3137 U/l (nv26-140).

An electromyography in January 2023 revealed upper and lower limbs fibrillations in proximal muscle with increase of polyphasic UM potentials of small amplitude and short duration, more accentuated in upper limbs.

In February 2023 a chest high resolution (HRCT) chest showed central bronchiectasis, and global spirometry revealed alveolo-




Fig. 1. Representative histopathological findings of muscle biopsy performed in January 2024.

A: Haematoxylin and eosin stain slide shows moderate changes in fibres size and shape, along with a lymphocytic inflammatory infiltrate located at endomysia (magnification 100x, scale bar 200µm). **B:** Gomori's trichrome staining (magnification 100x, scale bar 200µm). **C:** CD4 (magnification 100x, scale bar 200µm). **D:** CD8 (magnification 100x, scale bar 200µm). **E:** CD68 (magnification 100x, scale bar 200µm). **F:** HLA-ABC (magnification 100x, scale bar 200µm).

capillary diffusion reduction (DLCO 51%). The diagnosis was updated to an overlap of SSc and myositis and a treatment with oral high steroid dosage, immunoglobulin *i.v.* and oral mycophenolate was initiated, with an initial benefit.

Unfortunately, in September 2023, skin score and muscle markers relapsed (aldolase -260 U/mL- and CK -2320 U/l-), not responsive to prednisone and mycophenolic increased dosage.

In January 2024, a muscle biopsy showed changes in fibres size and shape, thickening of endomysia connective tissue and focal fibrosis, diffuse lymphocytic infiltrate, with scattered CD20+ cells in the interstitial compartment (Fig. 1).

In February 2024 heart MRI showed enhancement in the inferior junctional site and chest HRCT revealed an initial fibrous micronodule and a stagnation in thoracic oesophagus along its course, confirmed by oesophageal manometry that showed absence of contractility classified as Chicago

Class 4.0. Thus, RT (1000 mg) was administered in March 2024, with the second dose scheduled one month later.

At histological follow up (June 2024), inflammatory infiltrates disappeared, and fibres size and shape were normalised (Fig. 2). In July 2024 the patient reported significant improvement, normal lungs and joints at US, stable after one year. Only GERD persisted, even if reduced. Prostaglandins and immunoglobulin *i.v.* were stopped on May 2025, without relapse of myositis until now; amlodipine, mycophenolate and low dosage of steroids were maintained.

In conclusion, this case highlights a rare but significant event of a post-CV overlap of myositis and SSc. The patient's condition was resistant to conventional therapies, but she responded significantly to RT. This case underscores the importance of monitoring for challenging autoimmune postvaccine myositis for its differential diagnosis (8-10) and suggests that RT may be an effective treatment option in similar cases.




Fig. 2. Representative histopathological findings of post-treatment muscle biopsy performed in April 2024. No significant alteration was present morphologically, as well as no inflammatory infiltrates could be observed. **A:** Haematoxylin and eosin stain (magnification 100x, scale bar 200µm). **B:** Gomori's trichrome staining (magnification 100x, scale bar 200µm). **C:** CD4 (magnification 100x, scale bar 200µm). **D:** CD8 (magnification 100x, scale bar 200µm). **E:** CD68 (magnification 100x, scale bar 200µm). **F:** HLA-ABC (magnification 100x, scale bar 200µm).

F. BANDINELLI¹, MD, PhD
G. DALLAGIACOMA¹, MD
F. NOZZOLI², MD
M. CAPASSONI³, MD
R. NASSINI⁴, PhD

¹SOC of Rheumatology, Multi-Dimensional Department, Santa Maria Nuova and San Giovanni di Dio Hospitals, USL Tuscany Center, Florence;

²Department of Health Sciences, Section of Pathological Anatomy, University of Florence;

³SOC of Rheumatology, Multi-Dimensional Department, USL Tuscany Center, Prato;

⁴Department of Health Sciences and Headache Center, Clinical Pharmacology Unit, Section of

Clinical Pharmacology and Oncology, Careggi University Hospital, University of Florence, Italy.

Please address correspondence to:
Francesca Bandinelli
SOC di Reumatologia,
Ospedale Santa Maria Nuova,
USL Toscana Centro,
Piazza di Santa Maria Nuova 1,
50122 Firenze, Italy.
E-mail: francesca.bandini@gmail.com

Competing interests: none declared.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2026.

References

1. AMMITZBØLL C, THOMSEN MK, BARTELS LE *et al.*: COVID-19 vaccination before initiating rituximab treatment induces strong serological response in autoimmune rheumatic disease, reducing post-pandemic concerns about the impact of rituximab. *ACR Open Rheumatol* 2024; 6(8): 519-28. <https://doi.org/10.1002/acr2.11681>
2. BANDINELLI F, PAGANO M, VALLECOCCIA MS: Post-COVID-19 and post-COVID-19 vaccine arthritis, polymyalgia rheumatica and Horton's arteritis: a single-center assessment of clinical, serological, genetic, and ultrasonographic biomarkers. *J Clin Med* 2023; 12(24): 7563. <https://doi.org/10.3390/jcm12247563>
3. KIM HJ, KIM MH, PARK SJ, CHOI MG, CHUN EM: Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea. *J Allergy Clin Immunol* 2024; 153(6): 1711-20. <https://doi.org/10.1016/j.jaci.2024.01.025>. Erratum in: *J Allergy Clin Immunol* 2025; 155(3): 1057. <https://doi.org/10.1016/j.jaci.2025.01.001>
4. SYRMOU V, LIASKOS C, NTAVARI N *et al.*: COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. *Immunol Res* 2023; 71(4): 537-46. <https://doi.org/10.1007/s12026-023-09368-2>
5. BANDINELLI F, NASSINI R, GHERARDI E *et al.*: Small Fiber Neuropathy associated with post-COVID-19 and post-COVID-19 vaccination arthritis: a rare post-infective syndrome or a new-onset disease? *J Pers Med* 2024; 14(8): 789. <https://doi.org/10.3390/jpm14080789>
6. CARDELLI C, TRENTIN F, FATTORINI F *et al.*: Environmental triggers for idiopathic inflammatory myopathies: unravelling the known and unknown. *Clin Exp Rheumatol* 2025; 43(2): 186-92. <https://doi.org/10.55563/clinexprheumatol/0x1gob>
7. URSINI F, RUSCITTI P, ADDIMANDA O *et al.*: Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group. *RMD Open* 2023; 9(2): e003022. <https://doi.org/10.1136/rmdopen-2023-003022>
8. ZANFRAMUNDO G, SELVA-O'CALLAGHAN A, GONZÁLEZ-GAY MÁ, MONTECUCCO C, CAVAGNA L: Issues in the classification of myositis patients: an ongoing process. *Clin Exp Rheumatol* 2024; 42(2): 225-28. <https://doi.org/10.55563/clinexprheumatol/8u8p8x>
9. BANDINELLI F, DI CARLO M, COLANTUONO VA *et al.*: Post-COVID-19 small fiber neuropathy as a new emerging quality of life-threatening disease: a systematic review. *Microorganisms* 2025; 13(2): 328. <https://doi.org/10.3390/microorganisms13020328>
10. SALAFFI F, LOMMANO MG, BIANCHI B *et al.*: Trajectory of change in the severity of symptoms in patients with fibromyalgia over 24 months: exploratory analyses of a combination pharmacological intervention. *J Pers Med* 2024; 14(7): 689. <https://doi.org/10.3390/jpm14070689>